Autor(en)
Alexis Pascoe; Iyza F Baig; Andrew G Lee
Titel
Considering use of teprotumumab in thyroid eye disease patients
Teil von
  • Ophthalmology Times, 2018-10-01, Vol.43 (16), p.24-26
Ort / Verlag
Monmouth Junction: MultiMedia Healthcare Inc
Links zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen
A possible therapeutic agent was rituximab, but trials have shown conflicting evidence regarding its effectiveness5. [...]there is a need for an alternative treatment that can circumvent the current treatment limitations. IGF-IR and TSHR also form a receptor complex that when activated causes the activation of both receptors3. Because IGF-IR antibodies have been shown to mitigate the TSHR antibodies, blocking the stimulation of IGF-IR disrupts the pathway for the orbital tissues expansion of TED3.Therefore, due to its potential role in the pathogenesis of TED, treatment with a human IGF-IR monoclonal antibody, teprotumumab, was proposed. [...]the double-masked, randomized, multicenter, placebo-controlled trial by Smith et. al demonstrated that a 24-week course of teprotumumab benefits patients with moderate to severe Graves ophthalmopathy by enhancing quality of life as well as reducing their Clinical Activity Score and proptosis3.
Format
Sprache(n)
Englisch
Identifikator(en)
ISSN: 0193-032X
ISSN: 2150-7333

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX
Die Universität der Informationsgesellschaft